Back

Comparison of clinical outcomes with edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonist in patients with atrial fibrillation in Germany: a real-world cohort study

28 August 2020 (08:00 - 18:00)
Organised by:
Congress Presentation Part of: Arrhythmias, General ePosters Antiarrhythmic Drug Treatment ESC Premium Access ESC Congress 2020

About the speaker

Photo
Doctor Xiaocong Marston

Shanghai (China)

100 More presentations in this session

Presentation thumbnail
Beneficial electrophysiologic effects of sacubitril in different arrhythmia syndromes
Professor G. Frommeyer (Munster, DE)
Abstract Slides
Presentation thumbnail
Inflammation of conduction tissue in patients with arrhythmic phenotype of myocarditis
Doctor A. Frustaci (Rome, IT)
Abstract Slides
Presentation thumbnail
The pleiotropic effect of a deleterious DES mutation in familial atrial fibrillation and the role of PDE4DIP as a genetic modifier for heart block
Doctor M. Abou Ziki (New Haven, US)
Abstract Slides
Presentation thumbnail
Gen-editing to model Short QT syndrome type 5 using human-induced pluripotent stem cell-derived cardiomyocytes
Mr L. Maywald (Mannheim, DE)
Abstract Slides
Presentation thumbnail
Inducibility of atrial fibrillation is associated with disturbed activation pattern in bachmanns bundle
Ms L. van Staveren (Rotterdam, NL)
Abstract Slides

Access the full session

Session thumbnail
Arrhythmias, General ePosters

The Event

Event poster

ESC Congress 2020

28 August 2020 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Comparison of warfarin, dabigatran, rivaroxaban and apixaban for effectiveness and safety among elderly patients with atrial fibrillation: a nationwide cohort study
31 August 2020
thumbnail
Congress Session
From clinical trials to clinical practice: long-term effectiveness and safety of anticoagulation in patients with atrial fibrillation
27 August 2023
thumbnail
Congress Presentation
Edoxaban treatment in real-world practice is highly concordant with ESC atrial fibrillation guidelines: results from the non-interventional global ETNA-AF program
27 August 2021
thumbnail
Congress Presentation
Non-vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists (VKAs) in (morbidly) obese or low body weight patients with atrial fibrillation: a meta-analysis
23 April 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources